|
1
|
Park JH and Brentjens RJ: Adoptive
immunotherapy for B-cell malignancies with autologous chimeric
antigen receptor modified tumor targeted T cells. Discov Med.
9:277–288. 2010.PubMed/NCBI
|
|
2
|
Castro FV, Al-Muftah M, Mulryan K, Jiang
HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE and
Stern PL: Regulation of autologous immunity to the mouse 5T4
oncofoetal antigen: Implications for immunotherapy. Cancer Immunol
Immunother. 61:1005–1018. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kopylov U, Ben-Horin S, Zmora O, Eliakim R
and Katz LH: Anti-tumor necrosis factor and postoperative
complications in Crohn's disease: Systematic review and
meta-analysis. Inflamm Bowel Dis. 18:2404–2413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kawalec P, Mikrut A, Wiśniewska N and Pilc
A: Tumor necrosis factor-α antibodies (infliximab, adalimumab and
certolizumab) in Crohn's disease: Systematic review and
meta-analysis. Arch Med Sci. 9:765–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marchioni RM and Lichtenstein GR: Tumor
necrosis factor-α inhibitor therapy and fetal risk: A systematic
literature review. World J Gastroenterol. 19:2591–2602. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laharie D, Bourreille A, Branche J, Allez
M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J,
et al: Ciclosporin versus infliximab in patients with severe
ulcerative colitis refractory to intravenous steroids: A parallel,
open-label randomised controlled trial. Lancet. 380:1909–1915.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reinisch W, Sandborn WJ, Rutgeerts P,
Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers
WJ, Blank M, Lang Y, et al: Long-term infliximab maintenance
therapy for ulcerative colitis: The ACT-1 and −2 extension studies.
Inflamm Bowel Dis. 18:201–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jun Y, Hong Z and Jie T: The study of
mouse TNF-α functional domain and its neutralizing antibody binding
site. Prog Biochem Biophys. 36:4302009.
|
|
9
|
Amexis G and Young NS: Multiple antigenic
peptides as vaccine platform for the induction of humoral responses
against dengue-2 virus. Viral Immunol. 20:657–663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dechamma HJ, Dighe V, Kumar CA, Singh RP,
Jagadish M and Kumar S: Identification of T-helper and linear B
epitope in the hypervariable region of nucleocapsid protein of PPRV
and its use in the development of specific antibodies to detect
viral antigen. Vet Microbiol. 118:201–211. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thorlund K, Druyts E, Mills EJ, Fedorak RN
and Marshall JK: Adalimumab versus infliximab for the treatment of
moderate to severe ulcerative colitis in adult patients naïve to
anti-TNF therapy: An indirect treatment comparison meta-analysis. J
Crohns Colitis. 8:571–581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fausel R and Afzali A: Biologics in the
management of ulcerative colitis-comparative safety and efficacy of
TNF-α antagonists. Ther Clin Risk Manag. 11:63–73. 2015.PubMed/NCBI
|
|
13
|
Marehbian J, Arrighi HM, Hass S, Tian H
and Sandborn WJ: Adverse events associated with common therapy
regimens for moderate-to-severe Crohn's disease. Am J
Gastroenterol. 104:2524–2533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Can super-antibody drugs be tamed? Nature.
440:855–856. 2006.PubMed/NCBI
|
|
15
|
Rolinski J and Hus I: Breaking
immunotolerance of tumors: A new perspective for dendritic cell
therapy. J Immunotoxicol. 11:311–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park KB, Lim BK, Ye MB, Chung SY and Nam
JH: A peptide vaccine based on a B-cell epitope on the VP1 protein
of enterovirus 70 induces a strong antibody response. Acta Virol.
56:337–342. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haro I and Gómara MJ: Design of synthetic
peptidic constructs for the vaccine development against viral
infections. Curr Protein Pept Sci. 5:425–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Yang JM, Wang HJ, Ru GQ and Fan
DM: Synthesized multiple antigenic polypeptide vaccine based on
B-cell epitopes of human heparanase could elicit a potent
antimetastatic effect on human hepatocellular carcinoma in vivo.
PLoS One. 8:e529402013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Yang J, Fan D, Tao H, Wang H and
Yu T: Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted
CTL epitope and elicits potent immunological antitumor effects
in vitro with an 8-branched design. Oncol Rep. 29:1955–1961.
2013.PubMed/NCBI
|
|
20
|
Zhang J, Fan DM and Yang JM: Immunotherapy
targeting Heparanase-1 may be the the dawn of cancer sufferers. J
Gastroen Hepatol Res. 1:32012.
|
|
21
|
Zhang J, Yang J, Han X, Zhao Z, Du L, Yu T
and Wang H: Overexpression of heparanase multiple antigenic peptide
2 is associated with poor prognosis in gastric cancer: Potential
for therapy. Oncol Lett. 4:178–182. 2012.PubMed/NCBI
|
|
22
|
Zhang J, Yang J, Cai Y, Jin N, Wang H and
Yu T: Multiple antigenic polypeptide composed of heparanase B-cell
epitopes shrinks human hepatocellular carcinoma in mice. Oncol Rep.
33:1248–1256. 2015.PubMed/NCBI
|
|
23
|
Du L, Wang H, Yang J, Gao H, Zhou Y and
Tao H: T-helper epitope peptide improves immunological effects of
the B cell epitopes of human heparanase protein. Chin J Microbiol
Immunol. 869–872. 2008.
|
